Payment overview · 2025
General Payments
$1,420.94
41 reported records · 13 companies
Healthcare provider profile · identity verified
Arnold J Brender, MD
Allopathic & Osteopathic Physicians|General Practice · HUNTINGTON BEACH, CA · NPI 1396732053
Verified facts
What the public records show
CMS Open Payments records show Arnold J Brender, MD received $1,420.94 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $561.26 | 39.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.96 | 14.8% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $124.95 | 8.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $124.92 | 8.8% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.80 | 5.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.23 | 4.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.96 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.67 | 4.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.36 | 2.8% | 2 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $25.16 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.45 | 1.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.36 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.86 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,420.94 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $321.25 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $240.01 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $188.01 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $124.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $93.54 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $81.80 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.96 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.25 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 250 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 53 |
| Losartan Potassium | Losartan Potassium | 165 | 46 |
| Simvastatin | Simvastatin | 110 | 34 |
| Lisinopril | Lisinopril | 107 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 25 |
| Gabapentin | Gabapentin | 93 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 88 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 25 |
| Omeprazole | Omeprazole | 72 | 18 |
| Meloxicam | Meloxicam | 62 | 22 |
| Metformin Hcl | Metformin Hcl | 62 | 17 |
| Tramadol Hcl | Tramadol Hcl | 61 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Ibuprofen | Ibuprofen | 52 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 19 |
| Alprazolam | Alprazolam | 49 | 12 |
| Eliquis | Apixaban | 48 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 14 |
| Allopurinol | Allopurinol | 43 | 12 |
| Montelukast Sodium | Montelukast Sodium | 43 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Famotidine | Famotidine | 41 | 14 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 14 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 17 |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Furosemide | Furosemide | 35 | 14 |
| Trazodone Hcl | Trazodone Hcl | 35 | 13 |
| Azithromycin | Azithromycin | 34 | 31 |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 17 |
| Azelastine Hcl | Azelastine Hcl | 25 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,420.94 · 41 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BARRIGEL, BREZTRI, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, EVENITY, GARDASIL 9, JARDIANCE, KRYSTEXXA, MOUNJARO, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error